HASBROUCK HEIGHTS, N.J., August 21 /CNW/ - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that further clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the meeting of the Western Section of the American Urological Association (AUA) to be held in Scottsdale, Arizona in October. The paper is authored by leading clinical research investigators from U.S. clinical trials of NX-1207. Further specific details on the upcoming presentation will be announced at a later date.
